Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $100.25 Average Price Target from Brokerages

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has received a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $100.25.

A number of research analysts have recently commented on the company. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price for the company in a research note on Thursday, August 13th. TD Cowen upped their price target on Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. BTIG Research increased their price objective on Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. raised their price objective on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Needham & Company LLC boosted their target price on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Amundi purchased a new position in Establishment Labs during the 2nd quarter valued at about $291,000. HighTower Advisors LLC grew its holdings in Establishment Labs by 3.2% in the second quarter. HighTower Advisors LLC now owns 9,517 shares of the company’s stock worth $817,000 after purchasing an additional 293 shares during the period. California State Teachers Retirement System grew its holdings in Establishment Labs by 8,625.7% in the second quarter. California State Teachers Retirement System now owns 1,930,124 shares of the company’s stock worth $165,624,000 after purchasing an additional 1,908,004 shares during the period. Kerrisdale Advisers LLC bought a new position in shares of Establishment Labs during the second quarter valued at approximately $1,750,000. Finally, Headlands Technologies LLC bought a new position in shares of Establishment Labs during the second quarter valued at approximately $1,174,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Price Performance

ESTA stock opened at $70.64 on Thursday. Establishment Labs has a 1 year low of $36.53 and a 1 year high of $97.59. The company has a market cap of $2.11 billion, a P/E ratio of -53.92 and a beta of 1.07. The firm has a 50-day moving average of $85.00 and a 200 day moving average of $74.91. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. During the same period in the previous year, the firm posted ($0.57) earnings per share. The business’s revenue was up 31.7% compared to the same quarter last year. On average, sell-side analysts forecast that Establishment Labs will post -1.15 EPS for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.